Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Pregnant women want genome guidance
MDedge Endocrinology
Opioids often prescribed in low-income areas
MDedge Endocrinology
What I learned from Navy SEALs about resilience
MDedge Endocrinology
Mediterranean diet cut Parkinson’s risk
MDedge Endocrinology
500 Women in Medicine: Part II
MDedge Endocrinology
A prescription for medicine’s gender inequality
MDedge Endocrinology
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Endocrinology
Trump targets abortion by denying family planning funds
MDedge Endocrinology
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Endocrinology
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Endocrinology